Moleculin Biotech (NASDAQ:MBRX) announced its earnings results on Tuesday. The company reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.01), Fidelity Earnings reports.
MBRX traded down $0.04 on Thursday, reaching $1.03. 1,751 shares of the stock were exchanged, compared to its average volume of 163,077. The company’s 50-day moving average price is $1.07 and its 200 day moving average price is $1.16. Moleculin Biotech has a fifty-two week low of $0.78 and a fifty-two week high of $3.15. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.11 and a quick ratio of 2.11. The firm has a market capitalization of $47.91 million, a PE ratio of -2.02 and a beta of 1.95.
Several research analysts recently weighed in on MBRX shares. ValuEngine downgraded Moleculin Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Oppenheimer started coverage on Moleculin Biotech in a research note on Thursday, October 17th. They set an “outperform” rating and a $2.00 target price on the stock. Finally, Maxim Group set a $3.00 target price on Moleculin Biotech and gave the stock a “buy” rating in a research note on Tuesday, August 20th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $4.33.
Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies.
See Also: Most Volatile Stocks
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.